Drägerwerk AG & Co. KGaA: Changes in the chair of the Dräger Supervisory Board

EQS-News: Drägerwerk AG & Co. KGaA

/ Key word(s): Personnel

Drägerwerk AG & Co. KGaA: Changes in the chair of the Dräger Supervisory Board

11.12.2024 / 14:06 CET/CEST

The issuer is solely responsible for the content of this announcement.

Changes in the chair of the Dräger Supervisory Board

Lübeck – Stefan Lauer, currently Chairman of all Dräger Supervisory Boards, has decided to step down as Chairman at the end of the year for health reasons. The Supervisory Board committees approved this move at their meetings today and passed the following resolutions:

From January 1, 2025, the chair of the Supervisory Board of Drägerwerk AG & Co. KGaA will be taken over by Maria Dietz, who has been a member of the Supervisory Board since 2018. The chair of all other committees (Joint Committee of Drägerwerk AG & Co. KGaA, Supervisory Board of Dräger Safety AG & Co. KGaA and Supervisory Board of Dräger Safety Verwaltungs AG) will be taken over by Professor Thorsten Grenz, who has been a member of all five Supervisory Boards since 2008 and remains Chairman of the Audit Committee. Stefan Lauer will remain Chairman of the Supervisory Board of Drägerwerk Verwaltungs AG.

Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG: “I am very pleased with this team effort by the Supervisory Board. In this way, we can ensure the Company’s ability to act and enable the current Chairman to heal. I would like to thank Maria Dietz and Thorsten Grenz for their willingness to take on additional responsibility and wish Stefan Lauer good health.”

Once Stefan Lauer has made a full recovery, the committees will once again decide on their chair.


11.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk

EQS-News: Evotec SE

/ Key word(s): Miscellaneous

Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk

11.12.2024 / 07:29 CET/CEST

The issuer is solely responsible for the content of this announcement.

 
  • Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases
  • LAB eN² is also expanding, adding Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions
 

Hamburg, Germany, 11 December 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.

“We are thrilled to be able to start work on these first projects, leveraging Evotec’s integrated drug discovery and translational platforms and Novo Nordisk’s deep disease understanding,” said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. “We are confident that LAB eN² will accelerate promising and innovative therapeutic concepts from bench to bedside in disease areas with significant unmet need. With Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and Icahn Mount Sinai, we welcome five additional stellar academic institutions to LAB eN². Together with our partner Novo Nordisk, this translational drug discovery accelerator provides an ideal breeding ground to take leading-edge academic science from concept to drug candidate.”

The first three selected projects will focus on driving forward research for different cardiometabolic conditions. The Boston University project, spearheaded by Drs. Victoria Herrera and Nelson Ruiz-Opazo and their collaborators Drs. Sushrut Waikar and Joel Henderson, will leverage unique insights into the role of inflammation within cardiometabolic diseases to discover pharmacological interventions, with a primary focus on chronic kidney disease (CKD) to start, and secondary focus on obesity. The research project led by Dr. Sloan Devlin at Harvard Medical School, in collaboration with Dr. Eric Sheu at Mass General Brigham, will characterize potential modulators of metabolic disease by investigating molecular mechanisms related to bariatric surgery. In the long term, the team aims to develop novel therapeutic candidates for the potential treatment of metabolic syndrome, including insulin resistance and type 2 diabetes. The Joslin Diabetes Center project, led by Dr. Peng Yi, Investigator at Joslin Diabetes Center and Assistant Professor of Harvard Medical School, will focus on type 1 diabetes, with a novel target approach aimed at modulating autoimmune response. The selected projects are initially funded with a Discovery Award to reach key pre-clinical value-inflection points. After reaching key pre-clinical milestones projects can be considered for additional funding up to the IND application stage and Novo Nordisk has the option to further develop and license specific programs.

“We have been so impressed by the scientific ideas that have been uncovered through this program and our ongoing collaboration with our academic partners,” said Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub. “The first selected projects offer novel approaches to address chronic cardiometabolic conditions, and we look forward to working with the primary investigators to advance their research. We launched LAB eN² with the intention to help bridge the translational research gap – we’ve been pleased with the progress so far and with the addition of five institutions, we have the opportunity to further our ability to drive more scientific ideas forward.”

Evotec and Novo Nordisk launched LAB eN² in September 2023 together with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess Medical Center. Under the expansion, researchers from Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and Icahn Mount Sinai can now also apply to LAB eN² with their projects. Leveraging access to Evotec’s integrated R&D platform and Novo Nordisk’s deep disease understanding, LAB eN² provides funding to design a drug discovery program and identify a therapeutic candidate across a range of therapeutic modalities.

About LAB eN²
LAB eN² was created to provide a solution-focused pathway for academic researchers, with a mission to accelerate the translation of their academic discoveries into investigational new drug (“IND”) candidates for cardiometabolic diseases as well as rare blood and rare endocrine disorders. LAB eN² provides funding, scientific expertise, and technology to help advance product concepts through pre-clinical proof of concept, at which point successful therapeutic product candidates may be selected by Novo Nordisk for further investment and development. Participating academic institutions work under a common governance framework with the goal of accelerating ideas easily. Research concepts are selected for LAB eN² support based on proposals from investigators at the participating academic institutions and are jointly developed and executed by the academic investigators, Evotec, and Novo Nordisk’s Bio Innovation Hub in Cambridge, Massachusetts, an R&D unit designed to work with academia, emerging biotechs, and established companies to uncover medical answers. For more details on LAB eN², please visit: https://laben2.com/.
 

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com 

Media

Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com


11.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group

EQS-News: Gerresheimer AG

/ Key word(s): Mergers & Acquisitions

Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group

11.12.2024 / 08:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group

  • Complementary product portfolio and broad footprint of production sites in Europe
  • Strengthening the market position as a full-service provider for the pharma and biotech industry
  • Strategic reset of Moulded Glass business

Düsseldorf, December 11, 2024 – Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group announced in May 2024. The closing was preceded by the fulfillment of customary closing conditions. Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer. With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries. Gerresheimer expects the acquisition to be accretive to the Group’s Adj. EBITDA margin and Adj. EPS from the first year onwards through synergies. On February 26, 2025, Gerresheimer will publish a new guidance for the combined company together with the results for the financial year 2024.

“Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions.”

Complementary, attractive product portfolio

In 2023, Bormioli Pharma generated sales of around EUR 371 million and an Adj. EBITDA margin of around 22%. The company manufactures pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems. In the plastics segment, Bormioli Pharma is one of the leading suppliers of pharmaceutical plastic systems and solutions. In the glass segment, Bormioli Pharma has an attractive portfolio for parenteral and other pharmaceutical primary packaging.

Strategic reset of Moulded Glass business

The acquisition creates a new, strong Moulded Glass unit with a diversified product portfolio for the pharmaceutical, cosmetics, food and beverage industries. This globally active unit offers new options for a strategic reset for the best growth prospects and competitiveness, which will be evaluated in the coming months.

New guidance for combined company in February 2025

Bormioli Pharma will become part of the Gerresheimer Group and will be fully consolidated retroactively as of December 1, 2024, the start of Gerresheimer’s new financial year 2025. Therefore, on February 26, 2025, together with the results for the financial year 2024, Gerresheimer will publish a new guidance for 2025 and a new mid-term guidance for the combined company.     

 

About Bormioli Pharma

Established in 1825, Bormioli Pharma is a leading pharma primary packaging manufacturer serving the industry with complete solutions, including glass and plastic bottles, plastic and aluminum closures and accessories. Bormioli Pharma’s products are designed and manufactured to drive innovation and deliver effective solutions to the growing challenges of sustainability. Bormioli Pharma has become part of the Gerresheimer Group in December 2024, an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. Gerresheimer operates over 40 production sites in 16 countries in Europe, America and Asia and currently employs around 13,400 people.

www.bormiolipharma.com

 

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets.  The Group generated revenues of around €2bn in 2023 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).   www.gerresheimer.com

Contact Gerresheimer AG

Media  
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

marion.stolzenwald@gerresheimer.com
Investor Relations  
Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

 
Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187
gerresheimer.ir@gerresheimer.com


11.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Conference call on the results for the 4th quarter 2023/2024 (ending 30 September 2024) on 19 December2024

EQS-News: Douglas AG

/ Key word(s): Annual Results/Conference

Conference call on the results for the 4th quarter 2023/2024 (ending 30 September 2024) on 19 December2024

10.12.2024 / 21:17 CET/CEST

The issuer is solely responsible for the content of this announcement.

Conference Call Invitation

Conference call on the results for the 4th quarter 2023/2024 (ending 30 September 2024) on 19 December2024

Düsseldorf, 10 December 2024 – The DOUGLAS Group, Europe’s number one omnichannel destination for premium beauty, invites you to an analyst and investor update call on the fourth quarter 2023/2024 on 19 December 2024.

 

The conference call on the results will be held at 11:00 a.m. CEST on 19 December 2024.

To participate in the conference call, please make use of one of the following options:

  • To participate in the audio conference, please use this link to register for the conference call.
    • Please use this webcast link to follow the presentation when dialed in.
  • You can follow the webcast with audio via this link.

 

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,870 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom – DOUGLAS 2026”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2022/23, the DOUGLAS Group generated sales (net) of 4.1 billion euros and employed around 18,000 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.
 

Investor Contact

Stefanie Steiner
Director Investor Relations and M&A
Phone: +49 211 16847 8594
Mail: ir@douglas.de


10.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

aap informs about the invitation to the Annual General Meeting on January 15, 2025

EQS-News: aap Implantate AG

/ Key word(s): AGM/EGM

aap informs about the invitation to the Annual General Meeting on January 15, 2025

09.12.2024 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap” or “Company“) informs about the invitation to the Annual General Meeting published today, which will take place on January 15, 2025 in presence at the Company’s headquarters in Berlin.

In particular, the Management Board and Supervisory Board will present the annual financial statements, which have now been adopted, the approved consolidated financial statements and the combined management report for the individual and consolidated financial statements for the 2023 financial year to the Annual General Meeting and will also propose a resolution on the discharge of the Management Board and Supervisory Board for the 2023 financial year.

In addition, the Supervisory Board will propose the election of a new auditor for the 2024 financial year, as already communicated in the Company’s announcement dated December 3, 2023.  The Supervisory Board and its Audit Committee expressly welcome the decision of the previous auditor not to carry out the audit of the annual and consolidated financial statements for the 2024 financial year and the opportunity to work with a new auditor in the event of an election.

Finally, the Management Board and Supervisory Board will present the audited remuneration report prepared for the 2023 financial year to the Annual General Meeting for discussion.

The Annual General Meeting with the presentation of the adopted annual financial statements for 2023 will result in a uniform dividend entitlement for all shares currently issued. As a result, the Company will be able to apply for all previously unlisted shares to be admitted to trading on the regulated market under ISIN: DE000A3H2101. The Company expects this to further increase the liquidity of the Company’s listed shares.

Further details and the complete agenda of the Annual General Meeting can be found in the invitation and in the documents published on the aap website (www.aap.de).

 

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –
 

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both through distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

 

Forward-looking statements

This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

 

If you have any questions, please contact:
aap Implantate AG; Rubino Di Girolamo; Chairman of the Management Board/ CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 290; Email: r.digirolamo@aap.de


09.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region

EQS-News: Formycon AG

/ Key word(s): Agreement

MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region

09.12.2024 / 06:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Presse Release // December 09, 2024
 

MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, Formycon’s Biosimilar to Stelara®1 (ustekinumab), in the Middle East and North Africa (“MENA region”).

MS Pharma is a leading regional pharmaceutical company in the MENA region and specializes in the distribution of biotechnological as well as generic drugs. The company will have rights to license, commercialize and produce FYB202 locally at its new Biosimilars site in Saudi Arabia for the Gulf Cooperation Council (GCC) countries as well as further countries of the MENA region. In February 2023, Formycon entered into a license agreement with Fresenius Kabi for the commercialization of FYB202 in key global markets. As part of this agreement, Formycon retained the rights to separately out-license FYB202 for commercialization in specific countries of the MENA region.

“Since the launch of our Lucentis®2 biosimilar FYB201 in the MENA region, we have established a very successful partnership with MS Pharma which was recently strengthened by adding the second ophthalmic biosimilar FYB203 (aflibercept) to this collaboration. It is our great pleasure to announce that we have now signed a further license and supply agreement with MS Pharma and added our FYB202 / ustekinumab biosimilar to this alliance. We are convinced that MS Pharma’s strong presence in the MENA region will support a good up-take of FYB202 as an effective, safe and cost-efficient treatment option for the numerous patients suffering from severe, chronic inflammatory diseases in the Middle East and North Africa. Formycon will receive an upfront payment as well as royalty payments from sales according to the agreement”, said Nicola Mikulcik, CBO of Formycon AG.

“Expanding our biosimilar pipeline with ustekinumab enables us to address additional therapeutic areas within our specialty business, enhancing patient access to these vital treatments across the MENA region. Our successful collaboration with Formycon continues to grow stronger, and the addition of new products fortifies our pipeline further. Crucially, all our biosimilar products will be manufactured locally at our state-of-the-art facility in Saudi Arabia, ensuring a reliable local supply and aligning with the Kingdom’s ambitious biotech strategy.” said Kalle Känd, CEO of MS Pharma.

In September 2024, both the U.S. Food and Drug Administration (FDA) and the European Commission granted approval for the ustekinumab biosimilar FYB202. MS Pharma plans to submit for regulatory approval in MENA countries at the earliest opportunity.

Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 and is used in the treatment of severe inflammatory diseases in the fields of gastroenterology, dermatology, and rheumatology.

——–

  1. Stelara® is a registered trademark of Johnson & Johnson.
  2. Lucentis® is a registered trademark of Genentech Inc.

 

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, received FDA approval; FYB202 is also approved in Europe. Another four biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich and is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/

About MS Pharma:
MS Pharma is a leading regional pharmaceutical company operating in the MENA region, well-positioned for fast business growth, with its headquarters in Amman, Jordan, and management offices in Zug, Switzerland. Established in 1989, MS Pharma has a robust presence in over 20 countries, and a diverse portfolio encompassing a wide array of generic, value-added, and biosimilar medicines, covering over 300 international nonproprietary names (INNs) for various treatments and maintaining more than 2000 market authorizations. MS Pharma’s operations are supported by three research and development centers and four manufacturing sites and boasts significant B2C capabilities with expansive reach in the Middle East and Africa. For further details, please visit our website: https://www.mspharma.com

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.


09.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Grünenthal successfully places new €500 million bond

EQS-News: Grünenthal GmbH

/ Key word(s): Bond/Issue of Debt

Grünenthal successfully places new €500 million bond

06.12.2024 / 13:17 CET/CEST

The issuer is solely responsible for the content of this announcement.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

 

Grünenthal successfully places new €500 million bond

 

Aachen, Germany, 6 December 2024 

Grünenthal GmbH (the “Company”) today announced that it has successfully placed its €500 million aggregate principal amount of 4.625% senior secured notes due 2031 (the “Notes”).

The Notes were rated ‘BB+’, ‘BB-‘ and ‘B1’ by the three major independent credit rating agencies Fitch Ratings, Standard & Poor’s and Moody’s Investors Service respectively.

This new financing will enhance Grünenthal’s capital structure and its maturity profile.

Gabriel Baertschi, CEO, said: “The placing of our latest bond strengthens our financial foundation and positions us to pursue our growth strategy. In addition, we gain the flexibility to invest in innovation, drive growth through strategic acquisitions, and continue delivering life-changing solutions for patients in need.”

Fabian Raschke, CFO, added: “Our latest bond reflects the financial community’s confidence in Grünenthal’s strategy and our ability to deliver sustainable growth. The transaction strengthens our capital structure, extends our debt maturity profile and enhances our flexibility to continue to invest – crucial steps to ensuring we continue creating value for patients, partners and stakeholders alike.”

The Company will use the proceeds from the Notes to refinance the €100 million outstanding under its revolving credit facility and to repurchase a portion of its outstanding notes due 2026 held in reliance on Regulation S under the Securities Act of 1933, as amended.

 

These materials are not an offer for sale of securities. The offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

The Notes and the related guarantees have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes and the related guarantees are being offered and sold (i) in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and (ii) in “offshore transactions” to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom, (ii) persons who are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or (iv) any persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or cause to be communicated (all such persons together being referred to as “relevant persons”). The investments to which this press release relates are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

The offer and sale of the Notes will be made pursuant to an exception under the Prospectus Regulation from the requirement to produce a prospectus for offers of securities. This press release does not constitute a prospectus within the meaning of the Prospectus Regulation or an offer to the public.

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA.

The distribution of this press release into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

 

Forward-looking statements

This news release may include “forward-looking statements” within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this news release, including, without limitation, those regarding the Company’s intentions, beliefs or current expectations concerning, among other things: the Company’s future financial conditions and performance, results of operations and liquidity; the Company’s strategy, plans, objectives, prospects, growth, goals and targets and future developments in the markets in which the Company participates or is seeking to participate. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate”, “believe”, “continue”, “ongoing”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “target”, “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that the Company’s actual financial condition, results of operations and cash flows, and the development of the industry in which the Company operates, may differ materially.

 

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.

 

More information: www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal

 

For further information, please contact:

Andrew Duncan, Deputy Head of Treasury and Head of Investor Relations
Tel.: +49 241 569 2073
Andrew.Duncan@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany
 
Florian Dieckmann, Head Global Corporate Affairs
Tel.: +49 241 569 2555
Florian.Dieckmann@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany
 

 


06.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Original-Research: Cantourage Group SE (von NuWays AG)

id=’remove_this_entry’>

id=’remove_this_entry’>

Original-Research: Cantourage Group SE – from NuWays AG

06.12.2024 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Classification of NuWays AG to Cantourage Group SE

Company Name: Cantourage Group SE
ISIN: DE000A3DSV01
 
Reason for the research: Update
Recommendation: BUY
from: 06.12.2024
Target price: 11.50
Target price on sight of: 12 months
Last rating change:
Analyst: Christian Sandherr

Full steam ahead, FY24 guidance raised; PT up

Topic: Cantourage raised its FY24e guidance following continued sequential growth throughout Q4 with November sales reaching € 7.2m, exceeding the previously strongest quarter by 31%.

Cantourage announced a particularly strong November sales figure of € 7.2m, a 31% increase compared to October (previous annual high). With this, Jan. to Nov. sales stand at € 42.9m, a roughly 80% increase compared to the full year 2023 figure. The driver behind this strong growth is the reclassification of medical cannabis (no longer qualified as a narcotic) in Germany, which took effect at the end of April and hence made obtaining a prescription notably easier. This is also visible in the estimated number of cannabis patients, which is seen to have doubled to 0.5-0.6m. Further, Cantourage is also experiencing a sharp increase in demand at its treatment facility in UK.

Taking into account continued strong demand throughout the remainder of the year as stated in yesterday’s press release, the company should be on track to reach Q4 sales of some € 19m (eNuW), a significant acceleration compared to before the legislative changes (Q1 sales of € 6.2m). The strong sales development is seen to increasingly feed down to the bottom line with a Q4 EBITDA margin expectation of 8.1% (eNuW) compared to a slightly negative figure last year.

More importantly, we also expect Cantourage to begin generating positive free cash flows. For FY24e, the company is seen to report € 1.5m, a notable improvement compared to FY23’s € -3.1m.

As a result of the strong operational ytd. performance management increased its FY24e guidance, now expecting € 46-50m sales (eNuW € 49.2m) and € 3-4m EBITDA (eNuW € 3.6m); old guidance: at least € 40m sales and € 2m EBITDA. While EBIT should still be slightly negative, it is important to note that is only due to the planned amortization of the operating GmbH value that was transferred into the SE as part of the listing in 2022.

Business to further scale during FY25e and beyond. Thanks to unbroken demand on the back of growing patient numbers and further de-bottlenecking at its processing sites, Cantourage should be well positioned to remain at the forefront of the dynamic market, reflected by our sales growth estimates. BUY with a new € 11.50 PT (old: € 10.00) based on DCF.

You can download the research here: http://www.more-ir.de/d/31501.pdf

For additional information visit our website: https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG – Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


id=’remove_this_entry’>

show this

Changes in Siegfried’s senior management team

Siegfried AG

/ Key word(s): Personnel

Changes in Siegfried’s senior management team

06.12.2024 / 06:30 CET/CEST

Media Release
Zofingen, December 6, 2024

Stefan Randl will join as Chief Scientific Officer and member of the Executive Committee as of January 1, 2025. He will succeed Jürgen Roos who has decided to leave the company to take a well-deserved sabbatical. Stefan joins from Evonik, where he has held various leadership positions in several regions over the past 16 years, most recently as Vice President Innovation Management Health Care, based in Frankfurt, Germany, and as Vice President Drug Substance, based in Indiana, US. He also headed Sales & Services for Health Care in Asia, based in Tokyo. He holds a PhD in Organic Chemistry from the Technische Universität Berlin. 

Olesia Silanteva has been appointed as Chief Human Resources Officer and member of the Executive Committee effective April 1, 2025. She will replace Irene Wosgien who is stepping down from her responsibilities as Chief Human Resources Officer. Olesia will join from Sandoz where she has been People & Organization (P&O) Head for the Technical Operations since 2020, overseeing almost 11000 employees across 18 sites. Olesia is an accomplished P&O professional with more than 20 years of experience driving large-scale operations and transformations across industries. Prior to her current role, she held a number of senior P&O roles at Novartis in Russia and Switzerland. Olesia holds a Corporate MBA from the Stockholm School of Economics and a Diploma in Teaching from Pskov Pedagogical Institute. 

Luca Dalla Torre will join the Executive Committee as Chief Legal and Sustainability Officer as of January 1, 2025. Luca joined Siegfried in 2012 and has since assumed growing responsibilities in the field of legal, intellectual property, compliance, and insurance. In addition, he has been holding the responsibility of Chairman of the Sustainability Board since 2021. Prior to joining Siegfried, he held senior positions with corporate law firms in Zurich and New York, with a focus on mergers and acquisitions and corporate law. Luca holds a PhD in law and a Bachelor of economics from the University of Berne. He also holds an LL.M. in corporate law from New York University and has recently completed a Professional Certificate in sustainability from MIT. 

Marcel Imwinkelried, Chief Executive Officer Siegfried: “I am very delighted with the additions to the Executive Committee. Stefan Randl has a deep understanding of our Drug Products and Drug Substances business and brings profound technical expertise to the team. Olesia Silanteva has an extensive and impressive track record in supporting and advancing people and organizations. Luca Dalla Torre has been instrumental in our very positive development over the last 12 years and will further sharpen our focus on sustainability. All three will strengthen our executive team and bring their ideas and energy to help us successfully continue our growth trajectory in line with our EVOLVE+ strategy. I would like to thank Jürgen and Irene for their valuable contributions to Siegfried’s journey of growth over the past years.” 

  • Stefan Randl will become Chief Scientific Officer  
  • Olesia Silanteva will join as Chief Human Resources Officer 
  • Luca Dalla Torre, currently General Counsel, has been appointed to the Executive Committee as Chief Legal and Sustainability Officer 

Contact

Financial Analysts:

Media:
Dr. Reto Suter Peter Stierli
Chief Financial Officer Head Corporate Communications
reto.suter@siegfried.ch peter.stierli@siegfried.ch
Tel. +41 62 746 11 35 Tel. +41 62 746 15 51
   
   
Siegfried Holding AG  
Untere Bruehlstrasse 4
CH-4800 Zofingen

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. 

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.

expect more
 

Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland

+41 62 746 11 11
info@siegfried.ch
www.siegfried.ch

 


End of Media Release


show this

Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

Marinomed Biotech AG / Key word(s): Corporate Action/Capital Increase

Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

05-Dec-2024 / 14:34 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Korneuburg, Austria, December 5, 2024 – Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company’s share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the “Second Capital Increase”). The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. A report on the intended exclusion of the subscription rights of existing shareholders (the “Report”) was published on the Company’s website from November 28, 2024 onwards, and on the electronic announcement and information platform of the Federal Government of Austria (“EVI”) on November 28, 2024. The issue price per new share is EUR 8 so that the total issue price amounts to EUR 670,000. The required Supervisory Board resolution for the Second Capital Increase under exclusion of statutory subscription rights can be passed no earlier than two weeks after publication of the Report. The Company had already provided information on a possible second capital increase in ad hoc announcements of September 2, September 15, September 18 and November 27, 2024.

All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.

+++ End of ad-hoc announcement +++

 

End of Inside Information


05-Dec-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com


show this